Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT04551131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04551131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 13, 2021
Completion date
August 31, 2026
Enrollment
10 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hemophagocytic lymphohistiocytosis